𝔖 Bobbio Scriptorium
✦   LIBER   ✦

VAD protocol for treatment of advanced refractory multiple myeloma

✍ Scribed by Scheithauer, W. ;Cortelezzi, A. ;Kutzmits, R. ;Baldini, L. ;Ludwig, H.

Publisher
Springer-Verlag
Year
1987
Weight
425 KB
Volume
55
Category
Article
ISSN
1432-0584

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Salvage treatment for patient with multi
Salvage treatment for patient with multiple myeloma refractory to alkylating agents
✍ Gomez, German A. ;Han, Tin ;Ozer, Howard ;Henderson, Edward S. πŸ“‚ Article πŸ“… 1985 πŸ› John Wiley and Sons 🌐 English βš– 455 KB

Sixteen patients with multiple myeloma refractory to alkylating agents were treated with vincristine 0.25 mg/m2 i.v. on days 1 to 4 and prednisone 1 gm/m2 on days 1 and 3. Chemotherapy was repeated every 2 weeks. Of 15 evaluable patients, five achieved a partial response and four stable disease. Thr

High serum lactate dehydrogenase level p
High serum lactate dehydrogenase level predicts short survival after vincristine–doxorubicin–dexamethasone (VAD) salvage for refractory multiple myeloma
✍ Miyuki Suguro; Yshinobu Kanda; Rie Yamamoto; Aki Chizuka; Tamae Hamaki; Tomohiro πŸ“‚ Article πŸ“… 2000 πŸ› John Wiley and Sons 🌐 English βš– 34 KB πŸ‘ 1 views

We evaluated possible prognostic factors just before salvage therapy with vincristine, doxorubicin, and dexamethasone (VAD) for 36 patients with refractory multiple myeloma. The median duration from diagnosis to the first VAD salvage was 14 months (range 2-76 months). Among parameters that have been